Intensity Therapeutics, Inc. Common stock
€3.431
EUR
Last updated on --.
24h volume33.15K
24h highest3.5022 EUR
24h lowest3.2492 EUR
24h Price movement-0.80%
INTS recent prices
24 Hours
-0.80%-€0.027536
30 days
-25.43%-€1.141
60 days
-29.24%-€1.382
90 days
-49.62%-€3.395
Key data
Previous close3.4592 EUR
Market cap10.21M EUR
Volume33.15K
P/E ratio--
Dividend yield (TTM)0.00%
Dividend amount--
Next ex-dividend date--
Next payment date--
EPS diluted (TTM)-3.4076 EUR
Net income (FY)-9.20M EUR
Revenue (FY)--
Last report dateMay 7, 2026
About Intensity Therapeutics, Inc. Common stock
HeadquartersSHELTON
Employees (FY)7.00
Net income per employee (FY)-1.31M EUR
Listed onNasdaq
INTS conversion tables
 |  |
|---|---|
| 0.5 INTS | 1.715 EUR |
| 1 INTS | 3.431 EUR |
| 5 INTS | 17.15 EUR |
| 10 INTS | 34.31 EUR |
| |
|---|---|
| 0.5 EUR | 0.1457 INTS |
| 1 EUR | 0.2914 INTS |
| 5 EUR | 1.457 INTS |
| 10 EUR | 2.914 INTS |
More to explore
Trending stock
Trending stock PERP
Trending stock token
FAQ
INTS is trading at €3.431, -0.80% over the last 24 hours. Track live moves on the price chart at the top of this page.
The INTS stock forecast depends on a mix of factors — broader market conditions, sector trends, and company-specific drivers like earnings, product cycles, and macro signals. INTS is currently trading at €3.431, -0.80% over the last 24 hours, which reflects how the market is pricing these factors today. For a longer-term outlook on INTS price action, review the 30-day, 60-day, and 90-day performance shown above, monitor momentum across the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, and watch overall market sentiment. Stock forecasts and price predictions are inherently uncertain — always DYOR.
P/E ratio (Price-to-Earnings, trailing twelve months) measures how much investors pay per dollar of earnings over the last 12 months. INTS's P/E ratio is currently -- — calculated by dividing its share price by its trailing 12-month earnings per share (EPS). A higher P/E suggests investors expect stronger future growth from INTS; a lower P/E may indicate the stock is undervalued or that the market is pricing in a weaker outlook. P/E ratios are most useful when compared against INTS's historical range and other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.
Intensity Therapeutics, Inc. Common stock's market cap is currently 10.21M EUR. Market cap is calculated as stock price × total shares outstanding.
Disclaimer
The social content on this page ("Content"), including but not limited to tweets and statistics provided by LunarCrush, is sourced from third parties and provided "as is" for informational purposes only. OKX does not guarantee the quality or accuracy of the Content, and the Content does not represent the views of OKX. It is not intended to provide (i) investment advice or recommendation; (ii) an offer or solicitation to buy, sell or hold digital assets; or (iii) financial, accounting, legal or tax advice. Digital assets, including stablecoins and NFTs, involve a high degree of risk and can fluctuate greatly. The price and performance of the digital assets are not guaranteed and may change without notice.
OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.
OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.
24h volume33.15K
24h highest3.5022 EUR
24h lowest3.2492 EUR
24h Price movement-0.80%
Start trade with INTS Perpetual
Sign up to trade